Meeting
2022 ASCO Annual Meeting
MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).
Authors
Leslie M. Randall
Massey Cancer Center, Richmond, VA
Leslie M. Randall , David M. O'Malley , Bradley J. Monk , Robert L. Coleman , Stephanie Gaillard , Sarah F. Adams , Linda R. Duska , Fabio Cappuccini , Heather Dalton , Robert W. Holloway , Marilyn Huang , Hye Sook Chon , Noelle Gillette Cloven , Adam ElNaggar , Roisin Eilish O'Cearbhaill , Steven E. Waggoner , Zebin Wang , Eric Zhi , Vivek Samnotra , Panagiotis A. Konstantinopoulos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03955471
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5573)
DOI
10.1200/JCO.2022.40.16_suppl.5573
Abstract #
5573
Poster Bd #
449
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase Ib study of IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer.
First Author: Lingying Wu
Poster
2019 ASCO Annual Meeting
Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).
First Author: Haider Mahdi
Poster
2023 ASCO Annual Meeting
Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).
First Author: Yoo Na Kim
Poster
2022 ASCO Annual Meeting
PemBOv trial: Pembrolizumab plus bevacizumab with or without pegylated liposomal doxorubicin-based chemotherapy in patients with platinum-resistant ovarian cancer.
First Author: Judith Michels